申请人:LEAD PHARMA CEL MODELS IP B V
公开号:WO2016193452A1
公开(公告)日:2016-12-08
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.